Geode Capital Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-73,410
| Closed | -$638K | – | 4179 |
|
|
2018
Q2 | $638K | Sell |
73,410
-17,874
| -20% | -$161K | ﹤0.01% | 3355 |
|
|
2018
Q1 | $925K | Buy |
91,284
+30,005
| +49% | +$252K | ﹤0.01% | 3154 |
|
|
2017
Q4 | $297K | Hold |
61,279
| – | – | ﹤0.01% | 3540 |
|
|
2017
Q3 | $278K | Hold |
61,279
| – | – | ﹤0.01% | 3556 |
|
|
2017
Q2 | $309K | Sell |
61,279
-1,278
| -2% | -$5.72K | ﹤0.01% | 3531 |
|
|
2017
Q1 | $297K | Buy |
62,557
+174
| +0.3% | +$879 | ﹤0.01% | 3510 |
|
|
2016
Q4 | $349K | Buy |
62,383
+3,833
| +7% | +$21K | ﹤0.01% | 3406 |
|
|
2016
Q3 | $324K | Buy |
58,550
+29
| +0% | +$192 | ﹤0.01% | 3433 |
|
|
2016
Q2 | $410K | Hold |
58,521
| – | – | ﹤0.01% | 3300 |
|
|
2016
Q1 | $386 | Sell |
58,521
-1,607
| -3% | -$11.8K | ﹤0.01% | 3356 |
|
|
2015
Q4 | $619K | Buy |
60,128
+8,145
| +16% | +$94.4K | ﹤0.01% | 3169 |
|
|
2015
Q3 | $612K | Buy |
+51,983
| New | +$574K | ﹤0.01% | 3125 |
|
|
2015
Q2 | – | Sell |
-48,350
| Closed | -$300K | – | 4002 |
|
|
2015
Q1 | $300K | Hold |
48,350
| – | – | ﹤0.01% | 3424 |
|
|
2014
Q4 | $270K | Hold |
48,350
| – | – | ﹤0.01% | 3463 |
|
|
2014
Q3 | $284K | Buy |
48,350
+2,000
| +4% | +$12.2K | ﹤0.01% | 3428 |
|
|
2014
Q2 | $317K | Sell |
46,350
-2,895
| -6% | -$19.4K | ﹤0.01% | 3356 |
|
|
2014
Q1 | $355K | Buy |
49,245
+650
| +1% | +$4.49K | ﹤0.01% | 3290 |
|
|
2013
Q4 | $321K | Buy |
48,595
+236
| +0.5% | +$1.61K | ﹤0.01% | 3262 |
|
|
2013
Q3 | $352K | Buy |
+48,359
| New | +$326K | ﹤0.01% | 3099 |
|
Geode Capital Management's JNP Position: Q3 2018 in Review
Geode Capital Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 73,410 shares — an estimated $638K sold.
Geode Capital Management first reported a position in JNP in Q3 2013 and held it in 19 quarters. The position peaked at $925K in Q1 2018. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Geode Capital Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Geode Capital Management sold 73,410 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $638K.
- Geode Capital Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 19 quarters.
- Geode Capital Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $925K in Q1 2018.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Geode Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.